Equillium_Square_Logo.png
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
June 11, 2021 07:00 ET | Equillium
Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical...
Equillium_Square_Logo.png
Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry
June 10, 2021 08:00 ET | Equillium
LA JOLLA, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Present at the JMP Securities Life Sciences Conference
June 09, 2021 08:00 ET | Equillium
LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases
June 07, 2021 08:00 ET | Equillium
LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11
June 03, 2021 08:00 ET | Equillium
Presentation and conference call will include topline data from all cohorts The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy LA JOLLA,...
Equillium_Square_Logo.png
Equillium to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET | Equillium
LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium Presents Multiple Posters at the 104th Annual Meeting of the American Association of Immunologists
May 17, 2021 08:00 ET | Equillium
Research highlights itolizumab’s novel mechanism of action and its effect on modulating T cell responses through inhibition of the CD6-ALCAM pathway The development of a pharmacodynamic biomarker...
Equillium_Square_Logo.png
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
May 13, 2021 16:02 ET | Equillium
Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus Cash runway into the second half of 2023 Multiple data and regulatory catalysts through the...
Equillium_Square_Logo.png
Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology Association
May 13, 2021 08:00 ET | Equillium
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Equillium Announces Three Abstracts Accepted for Presentation at the 104th Annual Meeting of the American Association of Immunologists
April 27, 2021 08:00 ET | Equillium
LA JOLLA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...